Hookipa Pharma Inc. held a special meeting of stockholders on July 29, 2025. During the meeting, stockholders approved the sale of certain assets of the company pursuant to an Asset Purchase Agreement with Gilead Sciences, Inc. Additionally, the liquidation and dissolution of the company, as outlined in the Plan of Dissolution, received approval. The proposal to adjourn the meeting, if necessary to solicit additional proxies, was also approved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.